Citius Pharma surges as anti-infective drug succeeds in late-stage study

Citius Pharmaceuticals

21/05/2024 12:50

** Shares of drug developer Citius Pharmaceuticals  CTXR.O 
rise 32% to 87 cents premarket 
    ** Co says its experimental antibiotic lock solution to be
used along with a primary treatment to treat catheter-related
bloodstream infections met the main goal in a late-stage study  
    ** The therapy, mino-lok, helped significantly prolong time
to catheter failure compared to standard-of-care therapy - CTXR 
  
    ** The therapy is a non-invasive treatment option compared
to catheter removal and replacement - CTXR
    ** CTXR says it expects to engage with the U.S. FDA to
determine further steps for Mino-Lok
    ** Up to last close, stock down ~13% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))